Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
REGULATORY
LDP Group Renews Call for Gender-Neutral HPV Vaccination
A group of Liberal Democratic Party (LDP) lawmakers on July 5 renewed their call for gender neutral HPV vaccination, urging the government to discuss the inclusion of males in the national program without waiting for the approval of a nine-valent…
To read the full story
Related Article
- Local Legislators Urge Routine HPV Shots for Males as LDP Group Renews Push
November 25, 2025
- Cost-Effectiveness Talks Continue on Expanding HPV Vaccinations to Males
September 26, 2025
- LDP Lawmakers Seek Early Male NIP Coverage for HPV Jabs
June 18, 2025
- No Inclusion of Males in National HPV Vaccinations for Now: MHLW Panel
May 23, 2024
- Lawmakers Request 4-Valent HPV Vaccination Program for Males to Minister
November 30, 2023
- Lawmakers Demand NIP Coverage for Male Use of 4-Valent HPV Vaccine
October 26, 2023
REGULATORY
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Ishin Urges “Special Charge” Scheme for OTC-Like Drugs, Eyes FY2026 Launch
December 15, 2025
- Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
- LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…